Oral semaglutide improves glycaemic control in people with typ...
BARCELONA, Spain, Sept. 17, 2019, /PRNewswire-AsiaNet/ -- Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions...
Authors: LATEST ASIANET NEWS RELEASES